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Death and cardiovascular events in patients with acute coronary
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CHU Robert Debré Reims, cardiologie, Reims, France
Background: Abdominal aortic aneurysm (AAA) is associated with
peripheral and coronary artery disease (CAD), however little is known about
the prognosis of patients who experienced an acute coronary syndrome (ACS)
and have an AAA. The aim of this study was to assess the prevalence of AAA
in patients hospitalized for ACS and to evaluate it was associated with an
increased cardio-vascular (CV) risk during follow up.
Methods: Between February 1, 2008 and March 30, 2009, patients
admitted for ACS with significant (≥50% stenosis) coronary lesions under-
went echography to check for presence of AAA. The AAA was defined as
dilation of infrarenal aorta with maximum antero-posterior diameter ≥30 mm.
During a 2 years follow-up we recorded all causes death, CV death and non-
fatals CV events. The combination of CV death and CV non-fatals events was
defined as the primary endpoint.
Results: Among 306 patients, 20 AAAs (6,6%) were diagnosed, of
average (±sd) diameter 33±3.7 mm, with a maximum diameter of 45 mm, non
requiring surgery. Follow-up at 2 years was available for 292 patients
(95,7%). During follow-up, 77 patients (25,5%) experienced an event (all
causes death or non-fatals CV event) : 23 deaths (7,6%), of wich 16 were from
CV cause, and 55 non-fatals CV event (18,2%). No event was due to AAA.
In univariate analysis age, abdominal aortic diameter, diabetes mellitus, previ-
ously known CAD and AAA were significantly associated with fatal and non-
fatal CV event (p<0,05). In multivariate analysis, age (OR=1.03; 95%CI
(1.008,1.058), diabetes mellitus (OR=1.7; 95%CI (1.05,2.7) and AAA
(OR=3.2; 95%CI (1.24,8.44) were independantly associated with the risk of
fatal or non-fatal CV event. Age (OR=1.18 95%CI (1.10,1.26) and AAA
(OR=4.17 95%CI (1.17,14.9) were the only independant predictors of all
causes death.
Conclusion: Our results show that in patients with CAD, the presence of
small non surgical AAA is associated with worse CV prognosis and higher all
causes mortality at 2 years.
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Background: Type 2 endoleaks after endovascular aortic repair (EVAR)
still represent a problematic issue for vascular surgeon to stop the aneurysmal
degeneration of the unsuccessfully excluded aneurysm. This study was
designed to assess the efficacy of secondary interventions performed on
continuing expanding abdominal aortic aneurysms (AAA) after EVAR with an
identified type 2 endoleak.
Methods: We retrospectively reviewed patients treated by EVAR for
AAA, in which follow-up data of more than 1 year were available. Endoleak
incidences, sac diameters, and secondary procedures were collected. Patients
with type 2 endoleaks and continuing expanding AAA were identified. Pri-
mary endpoint was the efficacy of these reinterventions on the postoperative
AAA diameter course. Secondary endpoints were the aneurysm-related mor-
bidity and mortality, and the cost effectiveness of these complementary proce-
dures.
Results: Out of 232 reviewed patients treated by EVAR for AAA, with a
mean follow-up of 3 years (37±30 months), 15 type 1 (6.5%), 94 type 2
(40.5%), and 8 type 3 (3.5%) endoleaks were identified. Among the 94 AAA
with a type 2 endoleak, 21 presented a sac regression (22.5%), 46 were stable
(49.5%), and 27 presented a sac enlargement (28%). Eight of these last sub-
group of patients had another type of endoleak associated that required partic-
ular treatments. Among the 19 patients presenting a type II endoleak
responsible for sac enlargement, 15 were indicated for embolisation proce-
dures, 1 was treated by immediate open repair, and 3 are still under surveil-
lance. Among the 15 patients treated by embolisation, 9 (60%) had still an
aortic sac enlargement postoperatively, requiring finally 6 open repairs with
one postoperative death. The mean extra cost by patient induced by secondary
procedures for type 2 endoleak was 27110±3098 Euros.
Conclusion: In our experience, endovascular reinterventions for type 2
endoleaks associated with an aortic sac enlargement after EVAR have a poor
efficiency on the stabilization of AAA diameter. These procedures entail extra
costs and morbidity that should be taken into account in their indication.
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Background: Troponin elevation in the setting of acute pulmonary embo-
lism (PE) is of small magnitude and short duration and can go unnoticed in
pts referred late after symptom onset.
Methods: Prospective, single-center registry of pts with confirmed inter-
mediate-risk PE, defined as at least 1 echocardiographic finding of right ven-
tricular (RV) dysfunction (endo-diastolic (EDRV)/left ventricular (EDLV)
end-diastolic diameter ratio >=1 in the 4-chamber view, paradoxical septal
systolic motion or pulmonary hypertension defined as RV/atrial gradient
>30mmHg), or positive troponin test. Combined in-hospital endpoint was
defined as death, non-fatal recurrent PE, or residual pulmonary vascular
obstruction (RPVO) ≥35%.
Results: 282 pts were included, age 66±14 years, 59% women, 174 (62%)
referred ≤5 days after symptom onset, 108 (38%) after >5 days. Troponin ele-
vation was observed in 126 (72%) treated within ≤5 days, in 60 (56%) treated
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after >5 days (p=0.004). A significant interaction was observed between
time since symptom onset and both troponin elevation and persistence of
EDRV/EDLV diameter ratio>1 at 48h. The negative predictive value of
troponin elevation was 85% in patients treated within 5 days of symptoms, but
fell to 70% in those admitted >5 days after symptom onset (p=0.002). Positive
troponin was an independent predictor of adverse outcome (OR=1.43 [1.08-
5.56]). ROC curves show that prognostic value of positive troponin test was
higher in pts referred ≤5 days than in pts referred >5 days after symptom onset
(p=0.01).
Conclusion: There is a significant relation between troponin elevation and
time since symptom onset in patients with intermediate-risk PE. Negative pre-
dictive value of troponin elevation is adequate in pts treated early (≤5 days)
but is suboptimal in pts treated >5 days after symptom onset.
Table – Results
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Management of hypertension by telemedicine: feasibility study and
results on 100 patients
Patrick Dary
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Introduction: According to the results of the national Health and study
conducted in 2006-07, the prevalence of hypertension among 18 to 74 years
old population is estimated at 31%. Among them, 20% are not treated. Among
the ones who are treated, 49% are not controlled.
Objectives: The goal of this observational study is to assess the feasibility
to follow up blood pressure by telemedicine for 100 hypertensive patients to
know the blood pressure profile and to adapt the treatment in real time to
improve control. This work won the award “1 Mission 1 million”.
Protocol of the study: The follow up by telemedicine of the blood pres-
sure figures is done by self measurement with 6 daily measures for not
controlled hypertensive patients. The follow up is organized in 3 phases:
inclusion, observation, treatment. Blood pressure is measured by oscillometry,
result are transmitted directly and available for consultation on a secure web
site.
Patient profile: Mean age is 68 years old, 44 men and 56 women, 19% are
not treated. 18% are treated for atrial fibrillation. Blood pressure at inclusion
is 175/92.
Observational Phase: 2 groups: 19 patients with a normal blood pressure
(135/75), 81 patients not controlled (163/86) who continue the follow up by
telemedicine during the treatment phase.
Treatment Phase: The adaptation of the treatment is achieved within
11 days with an average of 178/93 at inclusion, 163/86 during the observa-
tional phase and 144/78 after the last therapeutic adaptation. The decrease in
blood pressure between the 2 phases is 19 mm HG for the systolic blood pres-
sure and 8 mm for the diastolic one. It is obtained by adding another drug
(47%) or changing the therapeutic class (22%) with an increase in dosage.
46% reach the objectives (<140) and 54% stay with 154 systolic on average.
Conclusion: Telemedicine is a simple method for follow up of blood
pressure allowing a rapid adaptation of treatment to improve blood pressure
control. Telemedicine implyes an active participation of the patient.
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control of hypertension in type 2 diabetic patients? Contribution of
the ambulatory blood pressure in 100 patients
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Hypertension is frequently associated with type 2 diabetes. It accelerates
progression to micro and macro-angiopathy and is often not easy to control.
Aim: Evaluate the frequency of controlled hypertension among type 2 dia-
betes patients with known and treated hypertension, also describe the associ-
ated factors with poor blood pressure control.
Patients and method: Prospective study concerning 100 patients, who
have received a physical examination including a clinical measurement of
Blood pressure, a biological assessment and a 24 hours ambulatory blood
pressure monitoring (ABPM).
Results: The mean age was 60.8±8.1 years, the sex ratio (M / F)=0.59.
Hypertension was well controlled in only 37% patients, 21% had masked
hypertension and 14% a white coat hypertension. The concordance rate
between clinical measurement and ABPM was good: 62%. Subjects with
poorly controlled hypertension were significantly older (p<0.001), smoking
(p<0.02), and android morphotype (p <0.05). 45% of patients have lost the cir-
cadian rhythm, and were significantly more present in the uncontrolled group
(p=0.000), the morning peak of blood pressure was noted in 55% of patients,
and would also be more associated with uncontrolled hypertension (p=0.001).
Conclusion: Clinical measurement alone is not sufficient to estimate the
quality of blood pressure control, a systematic ABPM would be highly desir-
able in patients at high cardiovascular risk particularly to customize their anti-
hypertensive treatment and improve their cardiovascular prognosis.
<=5 days since 
symptom onset 
>5 days since 
symptom onset 
p
Sensitivity  72% (61.3-82.7)  51% (42.4-59.6)  0.005
Specificity  42% (44.5-49.5)  47% (39.1-54.9)  0.33
PPV  26% (18.4-33.6)  30% (22.2-37.8)  0.81
NPV  85% (78.4-91.6)  70% (63-77)  0.002
Figure – Method and results
